Abstract
The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) is a cAMP-activated chloride channel expressed in epithelia in the lung, intestine, pancreas, testis and other tissues, where it facilitates transepithelial fluid transport. In the intestine CFTR provides the major route for chloride secretion in certain diarrheas. Mutations in CFTR cause the hereditary disease cystic fibrosis, where chronic lung infection and deterioration in lung function cause early death. CFTR is a well-validated targeted for development of inhibitors for therapy of secretory diarrheas and activators for therapy in cystic fibrosis. Our lab has identified and optimized small molecule inhibitors of CFTR, as well as activators of ΔF508-CFTR, the most common mutant CFTR causing cystic fibrosis. High-throughput screening of small molecule collections utilizing a cell-based fluorescence assay of halide transport yielded thiazolidinone and glycine hydrazide CFTR inhibitors that block enterotoxin-mediated secretory diarrhea in rodent models, including a class of non-absorbable inhibitors that target the CFTR pore at its external entrance. Benzothiophene, phenylglycine and sulfonamide potentiators were identified that correct the defective gating of ΔF508-CFTR chloride channels, and other small molecules that correct its defective cellular processing. Small molecule modulators of CFTR function may be useful in the treatment of cystic fibrosis, secretory diarrhea and polycystic kidney disease.
Keywords: cystic fibrosis, CFTR, chloride channel, high-throughput screening, drug discovery, diarrhea, inhibitor, polycystic kidney disease
Current Pharmaceutical Design
Title: CFTR Chloride Channel Drug Discovery - Inhibitors as Antidiarrheals and Activators for Therapy of Cystic Fibrosis
Volume: 12 Issue: 18
Author(s): A. S. Verkman, Gergely L. Lukacs and Luis J.V. Galietta
Affiliation:
Keywords: cystic fibrosis, CFTR, chloride channel, high-throughput screening, drug discovery, diarrhea, inhibitor, polycystic kidney disease
Abstract: The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) is a cAMP-activated chloride channel expressed in epithelia in the lung, intestine, pancreas, testis and other tissues, where it facilitates transepithelial fluid transport. In the intestine CFTR provides the major route for chloride secretion in certain diarrheas. Mutations in CFTR cause the hereditary disease cystic fibrosis, where chronic lung infection and deterioration in lung function cause early death. CFTR is a well-validated targeted for development of inhibitors for therapy of secretory diarrheas and activators for therapy in cystic fibrosis. Our lab has identified and optimized small molecule inhibitors of CFTR, as well as activators of ΔF508-CFTR, the most common mutant CFTR causing cystic fibrosis. High-throughput screening of small molecule collections utilizing a cell-based fluorescence assay of halide transport yielded thiazolidinone and glycine hydrazide CFTR inhibitors that block enterotoxin-mediated secretory diarrhea in rodent models, including a class of non-absorbable inhibitors that target the CFTR pore at its external entrance. Benzothiophene, phenylglycine and sulfonamide potentiators were identified that correct the defective gating of ΔF508-CFTR chloride channels, and other small molecules that correct its defective cellular processing. Small molecule modulators of CFTR function may be useful in the treatment of cystic fibrosis, secretory diarrhea and polycystic kidney disease.
Export Options
About this article
Cite this article as:
Verkman S. A., Lukacs L. Gergely and Galietta J.V. Luis, CFTR Chloride Channel Drug Discovery - Inhibitors as Antidiarrheals and Activators for Therapy of Cystic Fibrosis, Current Pharmaceutical Design 2006; 12 (18) . https://dx.doi.org/10.2174/138161206777585148
DOI https://dx.doi.org/10.2174/138161206777585148 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Flavonoids in the Treatment of Diabetes: Clinical Outcomes and Mechanism to Ameliorate Blood Glucose Levels
Current Diabetes Reviews P-Selectin Antagonism in Inflammatory Disease
Current Pharmaceutical Design Mushrooms as the Source of Potential Antimicrobial Agents: A Review
Current Organic Chemistry Meet Our Editorial Board Member:
Current Drug Metabolism Health Benefits of Ipecac and Cephaeline: their Potential in Health Promotion and Disease Prevention
Current Bioactive Compounds Advanced Biomedical Techniques for Gene Delivery
Recent Patents on Biomedical Engineering (Discontinued) Lipoprotein(a) Management: Pharmacological and Apheretic Treatment
Current Medicinal Chemistry Extracorporeal Lung Assist for Sepsis and Acute Respiratory Distress Syndrome
Cardiovascular & Hematological Disorders-Drug Targets Anti-IL-1 β Therapies
Recent Patents on DNA & Gene Sequences MicroRNAs-Based Therapeutic Strategy for Virally Induced Diseases
Current Drug Discovery Technologies The Anti Inflammatory Effects of High Density Lipoproteins
Current Medicinal Chemistry New Strategy on Antimicrobial-resistance: Inhibitors of DNA Replication Enzymes
Current Medicinal Chemistry Mitochondrial Drug Targets in Cell Death and Cancer
Current Pharmaceutical Design Production of Retroviral Vectors: Review
Current Gene Therapy Nitrogen-Containing Macrocycles as Host Molecules for the Recognition of Undissociated Phenol Derivatives: Mechanism of Potentiometric Signal Generation
Combinatorial Chemistry & High Throughput Screening Sigma-1 Receptors: Potential Targets for the Treatment of Substance Abuse
Current Pharmaceutical Design Melittin: A Natural Peptide with Expanded Therapeutic Applications
The Natural Products Journal 2015 Update of Erectile Dysfunction Management Following Radical Prostatectomy: From Basic Research to Clinical Management
Current Pharmaceutical Design Targeting Peroxisome Proliferator-Activated Receptor Gamma for Generation of Antidiabetic Drug
Current Diabetes Reviews Anti-VEGF Drugs in Eye Diseases: Local Therapy with Potential Systemic Effects
Current Pharmaceutical Design